Introduction ment therapy a realistic possibility for CF. Heterozygotes Cystic fibrosis (CF) is an inherited condition affecting with a mutation in the CFTR gene have a normal phenoapproximately one in every 2000 Caucasians. The contype indicating that a single copy of the CFTR gene is dition is caused by mutations in the cystic fibrosis transsufficient for healthy lung function. Successful introducmembrane conductance regulator (CFTR) gene which tion of the CFTR cDNA into CF epithelial cells in vitro encodes a cAMP-regulated chloride channel expressed on and into CF transgenic mice corrected the defective the surface of epithelial cells. 1 The CFTR chloride channel cAMP-regulated chloride secretion. [4] [5] [6] [7] has an important role in regulating the transepithelial Several phase I clinical studies have been performed to transport of salt and water. Abnormality or absence of assess the transfer of the CFTR cDNA into the airways CFTR can result in disease in many organs of the body, of CF patients. The results of four clinical trials utilising but the major cause of morbidity and mortality in CF is adenoviral vectors have been published. The findings lung disease. Defective chloride secretion and elevated from these studies were equivocal. Some evidence of sodium absorption in the airways results in the developefficacy was shown in three trials, [8] [9] [10] although none was ment of thick mucus secretions in the lung and subobserved in a fourth study. 11 In addition, inflammatory sequent, chronic bacterial infection. 2 Despite advances in and immunological effects were observed at high doses. treatment, this condition still leads to an untimely death, Alternative, nonviral, gene delivery systems are receiving often in early adult life. All patients were pancreatic insufficient. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; Clinical score, Shwachman-Kulczycki clinical score. 29 Here, we describe a double-blinded, placebo-controlled tolerated the procedures well. The subjects had no sigstudy to test the safety and efficacy of DC-Chol/DOPE nificant changes in their vital signs, blood chemistry, liposomes to deliver CFTR cDNA to the nasal epithelium chest radiographs or respiratory function tests (Table 3) . of CF patients. The respiratory epithelium lining the There was no increase in inflammatory markers. The nasal cavity was targeted by direct instillation of the immunoglobulin and complement levels did not increase DNA-liposome complexes. This enabled us to monitor and were frequently reduced at the end of the study. Two closely for evidence of potential toxicity and correction patients (2 and 12) had symptoms of an upper respiratory of the CF ion transport defect. No inflammatory, tract infection during the third week of the study and immunological or other toxic effects were observed and rhinovirus was cultured from the nasal lavage fluid of CFTR function following gene transfer was demonstrated patient 12. Patients continued with their normal treatusing two independent techniques. The results provide ment, including the use of intravenous antibiotics by proof of concept for liposome-mediated gene transfer. patients 6, 7, 9 and 10. No patient complained of any pain or discomfort in their nose following dosing. White deposits were observed on the nasal epithelium
Results
of six patients (1, 2, 7, 9, 10 and 12) who each received DNA and liposomes (either CFTR or control vector Clinical evaluation plasmid). The deposits were most often seen on the nasal Twelve CF patients were enrolled in the study (Table 1) septum, occasionally the middle and inferior turbinates and attended the clinic as out-patients on 14 occasions (Table 2 ). All subjects completed the 4-week study and and were often removed by perfusion of fluids during thelial cells isolated on day 12 of the study (Table 2) .
Samples from three of the low dose CFTR cohort When the PD response to perfusion with Kreb's HEPES these deposits were residual DNA-liposome complexes dried on to the nasal epithelium, and were a result of the solution containing the sodium channel blocker amiloride (⌬PDamil) was measured, there were no significant postdirect instillation method of administration. 
⌬PDCl
− readily distinguishes between CF and non-CF One measurement from one patient receiving a low CFTR dose (Figure 4a ) and three measurements from one individuals (Figure 3a) . 16, 17 Typical recordings from a patient who received placebo (Figure 3b ), showed no patient receiving high CFTR dose ( Figure 4b) were restored into the range for non-CF subjects. Correction of changes after treatment. Certain individuals receiving CFTR treatment also showed no evidence of any change ⌬PDCl − into the non-CF range was seen for up to 7 days after treatment in patient 7 (Figure 4b 
or 5) and post-treatment (green: days 10, 11 or 13). (a) Comparison of typical CF (n = 15) and non-CF (n = 15) recordings. The traces represent the mean of n = 30 nostrils from each group with the data pooled every 15 s. Error bars represent s.e.m. This graph illustrates our CF and non-CF ranges for ⌬PDC1 − recordings. (b) Representative pre-and post-treatment recordings from patient 11 (placebo cohort). (c) Representative pre-and post-treatment recordings from patient 2 (high CFTR dose cohort). (d) Representative pre-and post-treatment recordings from patient 7 (high CFTR dose cohort). The data presented are selected to illustrate the best response seen after treatment (d), and examples of individuals who showed no change in recordings after treatment (b and c).
⌬PDCl − , consistent with CFTR gene transfer and efficacy nonviral delivery systems such as cationic liposomes are now receiving increased attention. (Figure 4a ). No significant post-treatment changes were observed in ⌬PDCl − measurements in the high CFTR To assess the safety and efficacy of DC-Chol/DOPE liposome-mediated CFTR gene transfer, we used the resdose or placebo cohorts (Figure 4b and c) . ⌬PDIso measurements were obtained in response to perfusion piratory epithelium of the nasal cavity as a surrogate tissue for the lung. This offered simple, noninvasive with a low chloride Kreb's HEPES solution containing the cAMP agonist isoprenaline. No significant post-treataccess to an epithelium with a histology and function similar to the tracheobronchial epithelium, and similar ment changes were observed in ⌬PDIso measurements in any of the dosing cohorts (data not shown).
CF-associated electrolyte abnormalities. 2 In this doubleblinded, placebo-controlled study a single dose of DNAliposomes was instilled directly on to the nasal epiDiscussion thelium. No serious adverse effects were observed. There was no significant change in any of the clinical paraGene therapy is being considered as a treatment for cystic meters measured and no evidence of an immunological fibrosis. Preclinical animal experiments have demonresponse. This is consistent with findings from other strated the feasibility of this approach; however, the studies in which DC-Chol/DOPE liposomes were admindevelopment of a safe and effective gene therapy for CF istered to patients. 13, 14 Although histopathology of epipatients will only become available after a series of clinithelial biopsies taken 7 days after treatment showed indical trials. 6, 7, 18, 19 The use of recombinant adenovirus as a viduals with mild chronic inflammation and one delivery system for CF gene therapy has been assessed individual with mild acute inflammation, these results in several clinical studies. [8] [9] [10] [11] 20 A meaningful comparison were all within the normal range for the biopsy site of the results has proved difficult due to extensive differchosen. Thus topical administration of DNA-liposomes ences in individual trial design. The efficacy observed in by direct instillation did not result in inflammation or these studies was variable and some potentially serious irritation of the nasal epithelium. One patient who safety issuses were raised. 21 In a placebo-controlled received a high CFTR dose (patient 12) described a short study, inflammation of the nasal epithelium was reported period of earache after the first treatment day. In an adenin two of three patients receiving the highest dose of oviral, CFTR gene transfer study, Knowles et al 11 also adenovirus. 11 Evidence of systemic and local toxicity was reported a patient with earache. Both studies employed observed after adenovirus vector was delivered to the a similar instillation method to deliver the treatment sollower airways. 20 The development of future adenoviral ution to the nose, although whether the cause of the earvectors with reduced immunogenicity may lessen the immune response in the patient. However, alternative ache was the result of the treatment administration, or 
15)). The genotype of this individual (⌬F508 homozygous) was reconfirmed experimentally by deletion-based and amplification refractory mutation-based allele-specific PCR assays.
due to a subsequent viral infection is unclear. In conTo assess functional CFTR gene transfer, we exploited differences in electrolyte transport between CF and nonclusion, and in contrast to current adenoviral vectors, DC-Chol/DOPE appears to provide a safe delivery CF individuals. The nasal epithelium of CF individuals shows increased sodium absorption and decreased chlorvehicle for gene transfer. However, the long-term safety of repeated administration can only be assessed by ide secretion compared to non-CF individuals. 17, 22 The functional effects of CFTR cDNA transfer were evaluated further clinical trials.
in vivo, by measurement of transepithelial PD, and ex of upper respiratory tract infection around day 15 and subsequently showed reduced basal PD measurements vivo, using SPQ fluorescence microscopy.
The electrophysiological measurement of transepi- (Figure 2b ; patients 2 and 12). It was therefore impossible to determine if these patients showed signs of correction thelial PD to evaluate efficacy in CF gene transfer clinical studies is well documented. 9, 11, 14 Together the four nasal using this technique. In order to circumvent these problems, this study PD parameters (basal PD, ⌬PDamil, ⌬PDCl − and ⌬PDIso) indicate the movement of sodium and chloride ions included the ex vivo technique of SPQ fluorescence microscopy as a complementary assay of efficacy. Halide across the nasal epithelium. 17, 23, 24 The ⌬PDCl − and ⌬PDIso measurements are both indicators of chloride secretion stimulated by cAMP-agonists is decreased in CF cells compared to non-CF cells, and SPQ analysis can transport and are reduced in CF individuals. We (Figure 3a) and others have shown that ⌬PDCl − as measreadily distinguish between them. 15 SPQ analysis was performed ex vivo on cells taken from the nasal epiured along the floor of the nose is the most consistent single discriminator between CF and non-CF, whilst thelium. Cells taken from three patients in the low CFTR dose cohort and two patients in the high CFTR dose ⌬PDIso measurements are more variable. 17 Therefore, an increase in ⌬PDCl − after treatment would be consistent cohort (Figure 1) showed an increase in fluorescence, consistent with the presence of functional CFTR. Since a with CFTR function following successful gene transfer.
In this study, the low CFTR dose cohort showed a change in SPQ fluorescence is a measurement of CFTR function in a single cell, whilst PD analysis reflects CFTR slight (approximately 2 mV), but statistically significant increase in ⌬PDCl − (P = 0.03, days 10-15 and P = 0.01, function across the intact epithelium, it is likely that SPQ analysis is a more sensitive assay of functional CFTR. days [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , consistent with a limited degree of CFTR gene transfer and efficacy (Figure 4a ). Inspection of postHowever, patient 5 showed correction of the ⌬PDCl − measurement, but no increase in SPQ fluorescence. A treatment ⌬PDCl − measurements from individual patients revealed that the response to CFTR treatment possible explanation is that gene transfer in the nasal cavity was uneven, and whilst PD was measured along the was variable. However, one measurement from a patient receiving a low CFTR dose (Figure 4a ) and three floor of the nose, SPQ analysis was performed on cells taken from above the inferior turbinate. This illustrates measurements from a patient receiving a high CFTR dose ( Figure 4b ) were in the range for non-CF subjects. The one difficulty in reliably assessing CFTR function following gene transfer. Importantly, SPQ analysis was not best post-treatment recordings in an individual receiving CFTR treatment showed complete correction of the CF affected by infections of the upper respiratory tract. Evidence of CFTR function could still be detected using SPQ chloride abnormality and were indistinguishable from a non-CF response (Figure 3d ). The correction of ⌬PDCl − analysis in patient 2, whilst PD measurements were severely affected by viral infection (Figure 1 and 2b) . This into the non-CF range was of approximately 7 days duration in patient 7 (Figure 4b ; days 11, 13 and 15) although study provided the first use of SPQ fluorescence analysis in a CF clinical gene transfer study and it has proved to patient 5 showed correction into the non-CF range 15 days after treatment (Figure 4a) . Thus, correction followbe a valuable technique. It may also be possible to further improve the method to make SPQ analysis a quantitating liposome-mediated CFTR gene transfer is transient. The reasons for this are unknown, but could be due to ive assay.
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The combined results of ⌬PDCl − correction (patients 5 decreased CFTR expression from the plasmid, the loss of the plasmid from the cells, or the loss of transfected cells and 7) and changes in SPQ fluorescence (patients 2, 3, 6, 7 and 10) showed evidence of functional CFTR gene from the nasal epithelium.
No change was observed in sodium-related measuretransfer in six out of the eight CFTR-treated patients. In addition, post-treatment changes in ⌬PDCl − reached ments (basal PD and ⌬PDamil) in the CFTR or placebo cohorts, indicating that despite successful correction of statistical significance for the low CFTR dose cohort (Figure 4 ). These electrophysiological data are the chloride defect there was no correction of the sodium defect by CFTR gene transfer. These results are consistent encouraging. Both in this study and that of Caplen et al, 14 the with previous experiments in cultured cells which demonstrated that whereas only 5% of cells need to express response to isoprenaline during nasal PD measurements in CFTR-treated patients was variable. The activation of CFTR for normal chloride secretion, a far greater proportion are required to restore normal sodium absorp-CFTR via the cAMP pathway is essential for the discrimination of CF and non-CF cells by the SPQ assay; 15 but the tion. 25, 26 Results from a clinical study to assess adenoviral CFTR gene transfer showed that although no evidence of switch to low chloride alone is sufficient to discriminate between CF and non-CF individuals by the PD assay. 17 correction was observed in ⌬PDamil, changes in basal PD reflected epithelial damage at high viral doses. 11 In this This difference may reflect the differing physiology of intact and isolated epithelial cells. study, the absence of basal PD changes after treatment supports our toxicological findings that even at the high-
The results from this study compare favourably with those obtained in the only other completed, liposomeest dose administered, delivery of DNA-liposomes did not damage the nasal epithelium. mediated CFTR gene transfer trial, in which limited gene transfer was also obtained. 14 A direct comparison can be The analysis of transepithelial PD is currently the standard method for studying CFTR gene transfer; however, made between the two studies, both of which used DCChol/DOPE liposomes to deliver plasmid DNA to the it has several limitations. One limitation is that sodiumrelated PD measurements are changed toward the nonnasal epithelium. There were minor differences in gene transfer formulations, such that a DNA:lipid (wt:wt) ratio CF range in patients with an upper respiratory tract infection. 23 This can complicate the interpretation of PD of 1:6, with a constant DNA:volume ratio was used in this study, whereas a DNA:lipid ratio of 1:5 with a changing measurements and negate data obtained during a clinical trial. Two individuals in this study had clinical evidence DNA:volume ratio was used by Caplen et al. 14 Other differences include the use in this study, of an alternative contained the human CFTR cDNA. This plasmid was shown to express functional CFTR protein in cells grown CFTR expression plasmid containing the Rous sarcoma virus 3′ long terminal repeat (RSV 3′LTR) rather than a in vitro and in an animal model. 19 Plasmid DNA was prepared at the Imperial Cancer Research Fund's Biotherasimian virus 40 promoter sequence, and the inclusion of a vector plasmid which did not express CFTR as a further peutics and Hybridoma Development Unit in London. The plasmid DNA was supplied sterile and essentially control. This additional control was important in this study to eliminate possible non-CFTR-specific effects of free of endotoxins (Ͻ1 EU/mg DNA), in single-use vials at a concentration of 0.667 mg/ml in Kreb's HEPES DNA-liposomes. Although only two patients received the control vector dose, we observed no toxicological buffer (pH 9.0). DC-Chol/DOPE cationic liposomes were prepared at effects and no interference in the PD efficacy measurements. In addition, we used direct instillation, rather than the University of Pittsburgh under conditions approved by the US Food and Drug Administration. 12 The DCaerosolisation, to target the DNA-liposome complexes to the nasal epithelium. This method limited deposition of Chol/DOPE liposomes (6:4 molar ratio of DC-Chol to DOPE) were made by a microfluidisation procedure, to the gene transfer reagents in the lungs and maximised contact time with the nasal epithelium. a final concentration of 2 mol/ml (equivalent to 1.2 mg/ml of total lipid) in endotoxin-free water. 28 The This study shows that the use of cationic liposomes to facilitate CFTR gene transfer to the nasal epithelium is transfection efficiency of the liposomes was assayed using HeLa cells and a plasmid expressing the chloramsafe, with no adverse effects observed even at the highest dose administered. This is in contrast to results from phenicol acetyl transferase reporter gene. 19 The DNA and liposomes were equilibrated to room temperature clinical studies using adenovirus. In addition, this study confirms that liposome-mediated gene transfer is feasible.
and mixed approximately 5 min before patient administration. Six out of the eight CFTR-treated patients showed evidence of CFTR function by transepithelial PD measurement or by SPQ analysis. Although the correction of the Dosing Four treatment regimens were compared in the trial. To CF ion transport abnormalities observed using these methods was transient, in one patient it was observed 15 ensure that the absolute concentration of DNA-liposomes was equivalent in each dose, different volumes of days after treatment. Nevertheless, if gene transfer proves successful in the lower airways, repeat dosing at relathe gene transfer reagents were administered. Four patients received a low CFTR dose, such that each nostril tively short intervals may be required for long-term, therapeutic benefit. It is expected that the efficiency of received 0.8 ml containing 40 g pTRIAL10CFTR2 DNA complexed with 0.4 mol DC-Chol/DOPE. Four patients this gene transfer system will improve as the mechanism of liposome-mediated transfection is better understood received a high CFTR dose (8 ml) containing 400 g CFTR DNA complexed with 4 mol DC-Chol/DOPE. and DNA-liposome formulations are optimised.
Two patients received control vector dose (8 ml) containing 400 g pTRIAL10 DNA complexed with 4 mol DC-
Materials and methods
Chol/DOPE and two patients received Kreb's HEPES Buffer (0.8 ml). The last two regimens constituted the plaSubjects cebo doses. Twelve CF patients (eight male and four female) with
The treatment solutions were delivered to the patients defined CF genotypes were enrolled in the study in four sessions spread over 2 days, such that a quarter (Table 1 ). All patients were over 16 years of age and gave of the total dose (0.2 ml or 2.0 ml as appropriate) was written informed consent. The patients continued with administered at each treatment session. The treatment their normal treatment during the 4-week study.
solutions were instilled directly on to the nasal septum using an MS16A syringe driver from Graseby Medical Study design (Watford, UK) via a soft, infant, 4F, 50 cm feeding cathThe study was approved by the UK Gene Therapy Adviseter from Portex (Hythe, UK). The patients lay on their ory Committee, the Medicines Control Agency and the left side with their head tilted down and the tube was appropriate Hospital Research Ethics Committees. Subplaced 2 cm into the right nostril. The solution was delivjects attended the clinic as out-patients on 14 occasions ered over a period of 15 min following which the patient (Table 2 ). In addition to the routine clinical examination remained in the same position for a further 15 min. After at each visit, patients were asked to report any sympsitting upright for a few minutes, the patient was repostoms. The subjects were randomly assigned a treatment itioned on their right side to instil the dose into the left regimen, such that both patients and investigators were nostril. Radioisotope studies demonstrated that whilst blinded to the treatment each subject received, and maximising the delivery to the nasal septum, this method remained blinded until after data analysis was gave a good spread of solution (using both 0.2 ml and completed.
2.0 ml volumes) throughout the nasal cavity with minimal mucociliary clearance into the nasopharynx over 30 min (data not shown). Gene transfer reagents Two plasmids, pTRIAL10 and pTRIAL10CFTR2 were used in this study. 19 Both plasmids contained an Nasal biopsy An epithelial biopsy was taken from the left nostril of expression unit consisting of the RSV 3′LTR promoter and the late polyadenylation signal from simian virus 40; each patient 6 days after dosing (day 15). The biopsy was taken using local anaesthesia. Cotton wool soaked with and the tetracycline-resistance gene incorporating a mutation to minimise expression in mammalian cells.
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5% cocaine solution was placed in the left nostril for 5 min. Cocaine paste (25%) was then applied directly to the The plasmids were identical except that pTRIAL10CFTR2 nasal septum. The biopsy (3-5 mm 2 ) was taken approxiperfusion (4 ml per min) of Krebs' HEPES solution (pH 7.4) were allowed to stabilise and were subsequently mately 3 cm back from the anterior nares on the nasal septum, the site of maximal exposure to the treatment recorded for 2 min. The perfusing solution was then changed sequentially to Kreb's HEPES plus 100 m amisolution. Histology of this region from control individuals revealed both transitional and ciliated, respiratory loride for 4 min, low chloride Kreb's HEPES (chloride replaced by gluconate) plus 100 m amiloride for 6 min, epithelia. The tissue was stored in formalin fixative and the tissue processed and stained with haematoxylin and and finally low chloride Kreb's HEPES plus 100 m amiloride and 10 m isoprenaline for 5 min. All solutions eosin for histological examination. Adjacent sections were immunostained with peroxidase-labelled monowere at room temperature. PD was recorded every second by a custom-built, battery-powered, data logger clonal antibodies against either neutrophil elastase (By87a; anti-neutrophil elastase), T cells (CD3; anti-CD3), (Logan-Sinclair, Rochester, UK) except for patients 5, 6, 7 and 8 on day 3, and patient 5 on day 5, where data B cells (JCB117; anti-CD79a) or macrophages (PGM1 or KP1; anti-CD68) according to standard pathology prowere recorded manually. Measurements were taken from both nostrils on each measurement day. Values of basal cedures and examined for evidence of inflammation.
PD, the change in PD after amiloride treatment (⌬PDamil), the change in PD after low chloride substiEx vivo electrophysiological measurements (SPQ analysis) tution (⌬PDCl − ) and the change in PD after isoprenaline treatment (⌬PDIso) were obtained by averaging the PD CFTR function was assessed in freshly isolated, nasal epithelial cells collected from the region between the middle values for the last 60 s in each solution from both nostrils. For discussion purposes, increases and decreases in PD and inferior turbinates by gentle brushing with a 3 mm cytology brush. Both nostrils were brushed and the cells refer to absolute magnitude of the PD. The Mann-Whitney U test for comparison between data sets was used as from each nostril combined. A proportion of the resulting cell suspension consisted of ciliated epithelial cells which in Caplen et al 14 and the null hypothesis of no difference was rejected at P Ͻ 0.05. Error bars indicate standard we and others have shown to possess ion transport properties characteristic of the airway epithelium. 15 Cells error of the mean. were loaded with the halide-sensitive fluorophore 6-methoxy-N-(3-sulphopropyl)-quinolium (SPQ) from
